IND Application

February 13, 2019

Another knock back for urea cycle disorders

Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.

Evaluate

Lilly plays it by ear

Another knock back for urea cycle disorders

Regenerating insulin-producing cells the next big thing in diabetes

Better late than never for Maxcyte’s one-day CAR-T approach

Double trouble sinks Oncomed as investors look to earlier assets

Patent twists and turns make Crispr no easier to value

Therapy focus – Curis thinks small to hit big immuno-oncology target

First human Crispr trial is a go, but don’t ask about the IP

Interview – Enterome has a good gut feeling about 2016

Therapeutic focus – Astra goes ROR fishing and hooks Orca

Interview – GW Pharma eyes breakthrough therapy as epilepsy data approach

Latest Reports

Pharma’s Biggest Spenders 2022 Infographic

Gene Editing: Overhyped or Unstoppable Tide?

Editor's Picks

Heightened US antitrust fears rattle biopharma

2023’s biggest launches: the story so far

Viking’s Voyage is not over yet

Gene editing: overhyped or unstoppable tide?

A slow (and low) year for FDA approvals